Dipeptidyl peptidase IV (DPPIV); homology with family of prolyl oligopeptidases; drug screening for enzyme inhibitors for DPPIV which could treat reproductive, inflammatory and metabolic disorders; antibodies for therapeutic or diagnostic use; host cells...
Adverse drug reaction ofDPP一4 inhibitors DPP一4抑制剂不良反应 安徽省立医院内分泌科胡圆圆叶山东 中国分类号587 1 文献标识码A 文章编号1672—2809 C2011)21—0046 04 美键词DPP一4抑制剂+胰升糖素样肚1 葡萄糖促胰岛素多肽 宴卤尿病是一种因胰岛紊绝 多效的酶,在体内分布广泛.其具 。l,口对或相对...
This article summarizes the knowledge of DPP-4 inhibitor and their multi-organ protective effects, to show the advantages and further development trends, and to provide reference for clinical use. 展开 关键词: Oral antidiabetic drug Dipeptidyl peptidase inhibitors Ⅳ(DPP-4 Multiple organ protection ...
The discovery of medicinal plant preparations as incretin pathway modulators and SGLT2 inhibitors have elicited a number of bioactive molecules, engendering the future anti-DN drug leads. Consequently, the review of relevant agro- economic or medico-economic plants, as source of SGLT2 inhibitors and...
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting systemReal-world FAERS data do not raise concern for muscular toxicity with DPP4-is in combination with statins, making a drug interaction ...
DPP‐4 inhibitorspharmacokineticspharmacodynamicstheoretical analysisproper usageDipeptidyl peptidase-4 (DPP-4) inhibitors are used clinically as therapeutic agents for the treatment of diabetes. To determine the rate of DPP-4 inhibition induced by these inhibitors, pharmacokinetic and pharmacodynamic parameters...
Alternative 1,4-benzodiazepine (DPP-IV) inhibitors; drug synthesis; preparation procedures; treatment of diseases such as type 2 diabetes, cataracts, glaucoma, Beninese prostate obesity, cancer; intermediates.Compounds derived from 1,4 - benzodiazepines; Preparation Process; Pharmaceutical Composition and ...
Safety Alerts for Human Medical Products - DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint PainNew information added to the WARNINGS AND PRECAUTIONS section of the drug labeling.
Drug-like reversible DPP-IV inhibitors used for the generation of the common structure-based pharmacophore with their corresponding IC50 values.Guasch, LauraJosé Ojeda, MaríaGonzálezAbuín, NoemíSala, EstherCeretoMassagué, AdriàMulero, Miquel...
Drug Safety and Availability - FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain[8-28-2015] The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and ...